All In Biotech

Drug Trial Radar · NCT04428788

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

131

Actual

Start

Jun 22, 2020

Primary completion

Oct 28, 2025

Study completion Oct 28, 2025

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

  • CC-94676Drug

    Specified dose on specified days

  • CC1083611Drug

    Specified dose on specified days

  • CC1083610Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteriaTime frame: From the time of consent at screening until 28 days after thesubject discontinues study treatment.
  2. Dose-limiting toxicity (DLT)Time frame: Up to 35 days
  3. Non-tolerated dose (NTD)Time frame: Up to 35 days
  4. Maximum tolerated dose (MTD)Time frame: Up to 35 days

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 116

    Stanford, California

  • Local Institution - 122

    Washington D.C., District of Columbia

  • Local Institution - 103

    Sarasota, Florida

  • Local Institution - 121

    Thomasville, Georgia

  • Local Institution - 108

    Baltimore, Maryland

  • Local Institution - 104

    Boston, Massachusetts

  • Local Institution - 117

    Ann Arbor, Michigan

  • Local Institution - 102

    Grand Rapids, Michigan

  • Local Institution - 112

    New York, New York

  • Local Institution - 109

    New York, New York

  • Local Institution - 105

    New York, New York

  • Local Institution - 106

    Durham, North Carolina

  • Local Institution - 120

    Allentown, Pennsylvania

  • Local Institution - 113

    Philadelphia, Pennsylvania

  • Local Institution - 107

    Dallas, Texas

  • Local Institution - 119

    Houston, Texas

  • Local Institution - 101

    San Antonio, Texas

  • Local Institution - 115

    Seattle, Washington

  • Local Institution - 111

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.